Statistics for Correction: The efficacy, safety, and efficiency of the off-label use of bevacizumab in patients diagnosed with age-related macular degeneration: protocol for a systematic review and meta-analysis
Total visits
| views | |
|---|---|
| Correction: The efficacy, safety, and efficiency of the off-label use of bevacizumab in patients diagnosed with age-related macular degeneration: protocol for a systematic review and meta-analysis | 33 |
Total visits per month
| views | |
|---|---|
| January 2025 | 1 |
| February 2025 | 0 |
| March 2025 | 0 |
| April 2025 | 0 |
| May 2025 | 0 |
| June 2025 | 0 |
| July 2025 | 0 |
File Visits
| views | |
|---|---|
| Correction_The efficacy, safety, and efficiency of the off-label use of bevacizumab in patients diagnosed with age-related macular degeneration_protocol for a systematic review and meta-analysis.pdf(legacy) | 9 |
| Correction_The efficacy, safety, and efficiency of the off-label use of bevacizumab in patients diagnosed with age-related macular degeneration_protocol for a systematic review and meta-analysis.pdf | 2 |
Top country views
| views | |
|---|---|
| China | 17 |
| United States | 7 |
| Portugal | 3 |
| Argentina | 1 |
| Finland | 1 |
| United Kingdom | 1 |
| Ireland | 1 |
| New Zealand | 1 |